Abstract Charcot-Marie-Tooth type 4C (CMT4C) is associated with mutations in the SH3 domain and tetratricopeptide repeats 2 (SH3TC2) gene, primarily expressed in Schwann cells (SCs). Neurotrophin-3 (NT-3) is an important autocrine factor for SC survival and differentiation, and it stimulates neurite outgrowth and myelination. In this study, scAAV1.tMCK.NT-3 was delivered intramuscularly to four-week-old Sh3tc2−/− mice, a model for CMT4C, and treatment efficacy was assessed at six months post-gene delivery. Efficient transgene production was verified with the detection of NT-3 in serum from the treated cohort. NT-3 gene therapy improved functional and electrophysiological outcomes including rotarod, grip strength, and nerve conduction velocity. Qualitative and quantitative histopathological studies showed that hypomyelination of peripheral nerves and denervated status of neuromuscular junctions at lumbrical muscles were also improved in the NT-3 treated mice. Morphometric analysis in mid sciatic and tibial nerves showed treatment-induced distally prominent regenerative activity in the nerve, and an increase in the estimated SCs density. This indicates that SC proliferation and differentiation, including the promyelination stage, are normal in the Sh3tc2-/- mice, consistent with the previous findings that Sh3tc2 is not involved in early stages of myelination. Moreover, in size distribution histograms the number of myelinated axons within the 3-6 µm diameter range increased, suggesting that treatment resulted in continuous radial growth of regenerating axons over time. In conclusion, this study demonstrates the efficacy of AAV1.NT-3 gene therapy in the Sh3tc2−/− mouse model of CMT4C, the most common recessively inherited demyelinating CMT subtype.